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Aim: Prostate cancer is the most commonly diagnosed malignancy and the second most common cause of cancer deaths in the
Western male population. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) modulate the remodeling of the
extracellular matrix (ECM). The imbalance between MMPs and TIMPs may lead to an emergence of pathological processes such as
cancer. In this study, the association between TIMP-2 (–418 G/C) and MMP-2 (–1306 C/T) polymorphisms and prostate cancer in the
Turkish population was investigated.
Materials and methods: Sixty-one prostate cancer patients and 46 healthy subjects were included in the study. DNA was isolated from 2
mL of peripheral blood taken from subjects, and genotypes were analyzed by the polymerase chain reaction-restriction fragment length
polymorphism method.
Results: The TIMP-2 –418 (GC) genotype was found in 15 cases (32.6%) in the control group and in 9 cases (14.8%) in the patients
group, and statistical significance was determined (P = 0.037, OR = 0.346). The MMP-2 –1306 (CT) genotype was found 2.17 times more
in the patient group than in the control group (P = 0.149, OR = 2.17).
Conclusion: Our results show that the TIMP-2 –418 (GC) genotype had a putative protective effect against prostate cancer.
Key words: Matrix metalloproteinases, prostate cancer, polymorphism, tissue inhibitors of metalloproteinases

1. Introduction
Cancer is one of the leading causes of death worldwide, and
it is estimated that 12.7 million cancer cases and 7.6 million
cancer deaths occurred in 2008. Among them, prostate
cancer is the second most frequent cancer type after lung
cancer and the sixth leading cause of death, accounting for
14% (903,500) of new cases and 6% (258,400) of deaths in
males in 2008 (1). Prostate cancer, a multifactorial disease,
is the most commonly diagnosed malignancy, and the
early diagnosis of prostate cancer is very important due to
its increasing incidence worldwide (2).
Matrix metalloproteinases (MMPs) are a group of 24
zinc-dependent endopeptidases capable of degrading
all kinds of extracellular matrix (ECM) and nonmatrix
substrates (receptors, apoptotic ligands, chemokines,
growth factors, etc.). The ECM is involved in vital biological
* Correspondence: kursatyay@yahoo.com

processes, such as cell proliferation, differentiation,
morphogenesis, tissue repair, and remodeling; it acts as
a reservoir of biological active molecules. Many MMPs
are associated with pathological destruction of ECM
components (3–6). The activity of MMPs is controlled
by specific endogenous inhibitors, called tissue inhibitors
of metalloproteinases (TIMPs). The group consists of 4
members and their involvement in cell signaling is well
established (7,8). The imbalance between MMPs and
TIMPs may lead to the emergence of pathological processes
such as arthritis and cancer. Several studies have shown
that MMP expression is elevated and the MMP/TIMP
physiological equilibrium is shifted in almost all human
cancer types. These findings lead to the idea of potential
involvement of the MMPs/TIMPs in cancer progression
and tumor-cell adhesion (9,10).
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The association of several MMP and TIMP
polymorphisms and cancer types has been previously
investigated. A vast amount of clinical data have shown
that among MMPs, the gelatinases (MMP-2 and MMP-9),
in particular, are associated with several types of human
neoplasms (11). The aim of this study was to evaluate the
potential role of the MMP-2 –1306 C/T (rs243865) and
TIMP-2 –418 G/C (rs8179090) gene polymorphisms in the
pathogenesis of prostate cancer in the Turkish population.
2. Materials and methods
2.1. Study subjects
Sixty-one patients with prostate cancer and 46 healthy
controls without cancer history admitted to the Urology
Departments of the Medical Faculty of Düzce University
and Abant İzzet Baysal University were included in the
study. The study was approved by the local ethics committee
and informed consent was obtained from the subjects
according to the Declaration of Helsinki. The demographic
characteristics (age and prostate-specific antigen) of the
participants were recorded.
2.2. DNA extraction and genotyping
The genotyping of MMP-2 –1306 C/T and TIMP-2
–418 G/C polymorphisms was performed as previously
described (12). Briefly, blood samples were obtained from
the study population and were collected in 2-mL tubes
with ethylenediaminetetraacetic acid. Genomic DNA was
obtained from peripheral blood leukocytes by using a
nucleic acid extraction kit (Vivantis, Malaysia) according
to the manufacturer’s instructions, and the samples were
stored at –20 °C until analysis by the polymerase chain
reaction-restriction fragment length polymorphism
(PCR-RFLP) method. The oligonucleotide primers to
amplify the promoter region of MMP-2 and TIMP-2 were:
5-CTTCCTAGGCTGGTCCTTACTGA-3’
(forward),
5’-CTGAGACCTGAAGAGCTAAAGAGCT-3’ (reverse)
and 5’-CGTCTCTTGTTGGCTGGTCA-3’ (forward),
5’-CCTTCAGCTCGACTCTGGAG-3’
(reverse),
respectively. PCR was performed in a total volume of 25 µL
with 0.5 µL of Taq DNA Polymerase (Fermentas, Lithuania).
The PCR mix was incubated for 5 min at 94 °C, followed by
35 cycles of 30 s at 94 °C and 45 s at 58 °C for MMP-2 –1306
C/T and 30 s at 94 °C and 45 s at 59 °C for TIMP-2 –418
G/C, 45 s at 72 °C, and a final step at 72 °C for 10 min.
The PCR products for MMP-2 –1306 C/T sites were
digested by BfaI (XspI) restriction enzymes, while TIMP2 –418 G/C sites were digested by AvaI (BsoBI) restriction
enzymes (NEB, UK). Digestion was accomplished by
incubation with 10 U of enzyme at 37 °C in a 25-µL total
reaction volume. The digested products were separated on
4% agarose gel stained with ethidium bromide.
The used primers produced a 193-bp fragment
containing the MMP-2 –1306 C/T site. The C allele
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recognizes 1 restriction site (188 + 5 bp), and the T allele
recognizes 2 restriction sites (162 + 26 + 5 bp). The used
primers produced a 304-bp fragment containing the TIMP2 –418 G/C site. The G allele recognizes 2 restriction sites
(230 + 51 + 23 bp) and the C allele recognizes 1 restriction
site (253 + 51 bp).
2.3. Statistical analysis
Statistical analyses were performed using PASW 18
statistical software (ver. 18.0 for Windows; SPSS Inc.,
Chicago, IL, USA). Categorical variables were compared
in 2 groups by using the Pearson and Fisher χ2 tests, and
the results were expressed as frequency and percent.
Binary logistic regression analyses were performed to
identify independent predictors for prostate cancer. Age
and genotype were cover rates. An independent-sample
t-test was performed to compare normally distributed
continuous variables in the 2 groups and these variables
were expressed as mean ± standard deviation. If
continuous variables were not normally distributed, the
Mann–Whitney U test was used and data were expressed
as medians (25th–75th percentiles); P-values of less than
0.05 were accepted as statistically significant.
3. Results
The age and prostate-specific antigen (PSA) values of the
study population are summarized in Table 1. The study
population consisted of 107 patients with a mean age of
70 ± 9.5 years. Among them, 61 patients with a mean age
of 71.25 ± 10.5 years formed the patient group and 46
patients with a mean age of 68.17 ± 7.6 years formed the
control group. No statistical significance was determined
(P = 0.092) in terms of age. However, the level of PSA
in the patient group was found to be significantly higher
compared to the control group (P = 0.000).
The MMP-2 –1306 C/T SNP genotype distribution
is shown in Table 2. The CC, CT, and TT genotypes were
found in 51 (83.6%), 7 (11.5%), and 3 (4.9%) cases in the
patient group, respectively. In the control group, the CC
and CT genotypes were found in 42 (91.3%) and 4 (8.7%)
cases, respectively. The TT genotype was not detected in
the control group. There was no association of genotype
frequency and prostate cancer. However, the genotype of
CT was found 2.17 times more in the patient group than in
the control group (P = 0.149, OR = 2.17).
The TIMP-2 –418 G/C SNP genotype distribution
is shown in Table 3. The GG and GC genotypes were
found in 52 (85.2%) and 9 (14.8%) cases in the patient
group, respectively. In the control group, the GG and GC
genotypes were found in 31 (67.4%) and 15 (32.6%) cases,
respectively. The CC genotype was not detected in either
patient or control groups. A statistical significance was
determined between the GC genotype and prostate cancer
(P = 0.037, OR = 0.346).
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Table 1. The characteristics of the patient and control groups.
Total (107)

Control (46)

Patient (61)

P

Age (years)

70 ± 9.5

68.17 ± 7.6

71.25 ± 10.5

0.092

PSA (ng/mL)

3 (1.2–10)

1.6 (0.94–2.0)

9 (6–19.8)

0.000

Table 2. MMP-2 –1306 C/T SNP genotype distributions in the patient and control groups.
Genotype

Total (107)

Control (46)

Patient (61)

P (χ2)

OR, CI*

P*

CC n (%)

93 (87)

42 (91.3)

51 (83.6)

Ref.

CT n (%)

11 (10.2)

4 (8.7)

7 (11.5)

TT n (%)

3 (2.8)

0

3 (4.9)

0.267

2.17 (0.75–6.2)

0.149

-

-

-

CT+TT n (%)

14 (13)

4 (8.7)

10 (83.6)

0.242

OR: odds ratio, CI: confidence interval, *: for logistic regression.
Table 3. TIMP-2 –418 G/C SNP genotypes distributions in the patient and control groups.
Genotype

Total (107)

Control (46)

Patient (61)

P (χ2)

GG n (%)

83 (77.6)

31 (67.4)

52 (85.2)

Ref.

GC n (%)

24 (22.4)

15 (32.6)

9 (14.8)

0.028

CC n (%)

-

-

-

GC+CC n (%)

24 (22.4)

15 (32.6)

9 (14.8)

OR*

0.346 (0.12–0.93) 0.037
-

0.028

P*

-

0.346 (0.12–0.93) 0.037

OR: odds ratio, CI: confidence interval, *: for logistic regression.

4. Discussion
Cancer, the plague of the 20th century, is a multifactorial
physical disease and decreases the patient’s quality of life.
Early diagnostic methods could help to overcome this
disease and therefore considerable effort has been made
in this respect. The genetic tendencies of individuals have
been studied for early diagnosis; the development and
progression of cancer is affected by inherited or somatic
genetic mutations (13,14). Despite the fact that prostate
cancer is the second leading cause of cancer-related deaths
in the Western world, its prevalence differs markedly in
various ethnic groups, suggesting the potential role of
genetic predisposition to prostate cancer (15).
MMPs and their inhibitors, TIMPs, are putative gene
families involved in the pathogenesis of cancer. The
MMP/TIMP balance is a critical biological process in the
maintenance of ECM components; a balance shift towards
MMPs promotes ECM degradation in cancer development
(16). To date, changed expression levels of several MMPs
and TIMPs in prostate cancer have been reported. The
involvement of MMP-9 in prostate cancer pathogenesis
was reported by Huang et al. (17). Membrane type 1-MMP

(MT1-MMP) with the capacity for pro-MMP-2 activation
is a vital agent and involved in the remodeling of the ECM.
The central role of MT1-MMP in inducing oxidative stress
in prostate cancer was proven by Nguyen et al. (18). Reis
et al. investigated the expression levels of MMPs and
TIMPs in 2 independent studies (19,20). They examined
the expression levels of MMP-2 and its regulators (TIMP2, MT1-MMP, IL-8, and MMP-9) and its inhibitor, TIMP1, in prostate cancer. The changed expression level of
these genes in prostate cancer was found in both studies.
Similarly, the differential expression of MMP-2 and MMP9 was investigated by several groups (21,22).
After elucidation of the potential roles of these genes
in the development of tumorigenesis, they have become
putative therapeutic and diagnostic targets, and several
studies have been conducted to clarify the relationship
between the polymorphisms of these genes and cancer
(23). Most of these studies succeeded in showing a
relationship between MMP and TIMP polymorphisms
and several cancer types, including colorectal (24), gastric
(25,26), head and neck (27), lung (28), and ovarian (29)
cancers.
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The aim of this study was to investigate the possible
impact of the MMP-2 –1306 C/T and TIMP-2 –418 G/C
polymorphisms in the pathogenesis of prostate cancer in
the Turkish population. The transitions of C to T and G to
C at the promoter region of the MMP-2 and TIMP-2 genes,
respectively, are very important in terms of gene expression
level, due to them being situated at the consensus sequence
for the Sp1-binding site (30). In addition, our study is the
first to investigate the relationship between prostate cancer
and MMP/TIMP polymorphisms.
Our results demonstrated that a statistically
significant difference was not determined between the
CT and TT genotypes of MMP-2 and prostate cancer, but
the CT genotype was found 2.17 times more often in the
patient group compared to the control group (P = 0.149,
OR = 2.17). It could be speculated that the MMP-2 (CT)
genotype might create a genetic tendency towards prostate
cancer. However, the GC genotype of the TIMP-2 gene was

found to be statistically significant (P = 0.037, OR = 0.346).
Similar results have been obtained by a study performed
in the North Indian population (31), which found that
the genotypes MMP-2 (CT) and TIMP-2 (GC) increased
genetic tendency towards prostate cancer by 1.68 and 0.79
times, respectively.
In conclusion, it might be speculated that MMP-2
–1306 C/T and TIMP-2 –418 G/C polymorphisms are
involved in the pathogenesis of prostate cancer, and TIMP2 –418 G/C more so. However, these results should be
supported by larger study groups. To elucidate the putative
roles in prostate cancer, the remaining MMP and TIMP
polymorphisms should be investigated.
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